Primovir and Paxista are immunosuppressive medications used to treat severe forms of arthritis such as rheumatoid arthritis and systemic juvenile idiopathic arthritis. This medication should only be used if the condition of a Virus Infect patient worsens despite other treatments such as steroids, anticoagulants, and so on.
Some virus infection patients will require hospitalization for severe respiratory illness, which can lead to life-threatening hypoxic respiratory failure.
The researchers enrolled over 4,000 hospitalized patients with hypoxia and systemic inflammation markers and treated them with standard-of-care therapy, including or excluding Primovir medication and Paxista medication. Patients taking Primovir and Paxista had lower mortality rates, were less likely to require mechanical ventilation, and were more likely to be discharged from the hospital.